Medartis Holding AG

BATS-CHIXE:MEDZ Stock Report

Market Cap: CHF 727.4m

Medartis Holding Past Earnings Performance

Past criteria checks 1/6

Medartis Holding's earnings have been declining at an average annual rate of -16.9%, while the Medical Equipment industry saw earnings growing at 1.9% annually. Revenues have been growing at an average rate of 13.2% per year. Medartis Holding's return on equity is 1.5%, and it has net margins of 1.8%.

Key information

-16.9%

Earnings growth rate

-17.7%

EPS growth rate

Medical Equipment Industry Growth-9.5%
Revenue growth rate13.2%
Return on equity1.5%
Net Margin1.8%
Next Earnings Update18 Mar 2025

Recent past performance updates

Recent updates

Revenue & Expenses Breakdown

How Medartis Holding makes and spends money. Based on latest reported earnings, on an LTM basis.


Earnings and Revenue History

BATS-CHIXE:MEDZ Revenue, expenses and earnings (CHF Millions)
DateRevenueEarningsG+A ExpensesR&D Expenses
30 Jun 24220413835
31 Mar 24216213430
31 Dec 23212113026
30 Sep 23205-313026
30 Jun 23198-712927
31 Mar 23190-612826
31 Dec 22183-612625
30 Sep 22178-312123
30 Jun 22173011622
31 Mar 22166311021
31 Dec 21160710320
30 Sep 2115399819
30 Jun 21146129419
31 Mar 2113769018
31 Dec 20128-18716
30 Sep 20125-38715
30 Jun 20123-48615
31 Mar 20126-18815
31 Dec 1913028915
30 Sep 1912738714
30 Jun 1912548414
31 Mar 1912348314
31 Dec 1812148213
30 Sep 1811928013
30 Jun 1811607813
31 Mar 1811107212
31 Dec 1710516711
31 Dec 16933549
31 Dec 15827479

Quality Earnings: MEDZ has a large one-off loss of CHF3.1M impacting its last 12 months of financial results to 30th June, 2024.

Growing Profit Margin: MEDZ became profitable in the past.


Free Cash Flow vs Earnings Analysis


Past Earnings Growth Analysis

Earnings Trend: MEDZ's earnings have declined by 16.9% per year over the past 5 years.

Accelerating Growth: MEDZ has become profitable in the last year, making the earnings growth rate difficult to compare to its 5-year average.

Earnings vs Industry: MEDZ has become profitable in the last year, making it difficult to compare its past year earnings growth to the Medical Equipment industry (39.9%).


Return on Equity

High ROE: MEDZ's Return on Equity (1.5%) is considered low.


Return on Assets


Return on Capital Employed


Discover strong past performing companies

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/12/23 22:00
End of Day Share Price 2024/12/23 00:00
Earnings2024/06/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Medartis Holding AG is covered by 10 analysts. 3 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Eric Le BerrigaudBryan Garnier & Co
Hugo SolvetBryan Garnier & Co
Christoph GretlerCredit Suisse